clinical outcomes in women with metastatic her2-low breast cancer in the real world
Published 2 years ago • 178 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:45
real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
-
1:16
her2-low expression in breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?
-
2:05
latest news in her2-low breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
1:33
questions remaining in the field of her2-low breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
0:31
remaining questions regarding her2-low breast cancer
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
2:14
survival in premenopausal hr /her2- breast cancer with micro-metastasis and 21-gene score
-
5:55
decision-making in metastatic her2 breast cancer
-
4:53
comparing therapy benefit from initially her2 positive or negative metastatic breast cancer patients
-
1:01
future of breast cancer care: her2 therapies in earlier settings & de-escalation
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
3:15
brain metastases in her2 breast cancer
-
1:11
her2climb: tucatinib efficacious against brain metastases in patients with her2 breast cancer